It wasn't bad timing. If biotech continues to take a beating, SRPT's share price will likely drop along with it, albeit maybe not as much as the rest of the sector. As awesome as this stock has performed, it isn't completely immune to the biotech meltdown. Raising at the 52-week high was wise.
Looks like a struck a nerve, huh? How do you feel about Hilary Clinton??
Yes, that's the exact logic I used. I didn't use any other logic. Only that. Like, I mean, I didn't consider that all of you suddenly reversed course from bullish to bearish today.
I will admit that it's possible that not all of these posters are the same, but I'd bet my left nut that at least a few are.
These guys love using underscores in their names. Total coincidence that they've each been posting as much negativity as possible today, right?
I feel embarrassed that I didn't make this connection before today.
Um, I argued the point AND attacked you. You just failed to realize that I argued the point. Because you're an ess for brains.
If you consider that SRPT pricing is at $39, then today's drop is pretty much inline with XBI and the rest of the smid biotech sector. If using $39 as the baseline for today's drop, SRPT is off 7%, which is also what XBI is off. Keeping things in perspective helps when the lunatics show up and start boo-hooing everything.
The cash raise was responsible and smart. Biotech is clearly out of favor right now and could be for awhile, so raising at the 52-week high was a no brainer.
I'd say if we can raise cash at $39 while the stock is trading at $35, then that's a pretty darn good deal. Am I missing something?
Definitely. Being up over 200% on the year (with a few flips here and there) is akin to abuse and torture. You are one smart cookie.
Never. It will never feel good. Your life is too precious to be subjected to the emotional distress of biotech investing. Sell SRPT and find peace with yourself, my friend.
Dear ess for brains:
Have you paid attention to the biotech sector over the past two months? If your answer is yes, then you should understand exactly why the company chose to raise money at their 52-week high. To expect SRPT to be completely immune to a continued sell-off is ignorant, and nobody knows how long this sell-off will last. The cash raise was a "duh" moment. If your answer to the question is no, then you shouldn't be investing. (You probably shouldn't be investing regardless. You seem a bit to emotional. Stocks don't go up in a continuous straight line, and SRPT has been an amazing investment since the beginning of the year. Quit acting like a crybaby.)
Use your brain and a little bit of logic. It'll do you some good.
I think you qualify as the whiniest, most ignorant poster on the board.
Well then I guess 99.99% of every other biotech with no drugs on the market has incompetent management as well. Good call.
Calm down. This is the safe route. Far too many biotechs skip raising cash thinking their upcoming catalyst is a lock, and then they end up screwed. Wall Street will view this positively.
What I'm saying is that the data doesn't differentiate between sale or cover. The only reliable, accurate short numbers available to the public are the bi-monthly reports. Daily data is essentially meaningless if you are retail.
You'll know everything as it happens. It will be broadcast live by Adam Feuerstein and probably a few of the DMD groups.
The problem with those numbers is that they include covers. So that doesn't mean there are another million short. I'd guess more are covered than new shorts.
It has nothing to do with big pharma. It has to do with algos and HFTs. But stay delusional. You're good at it.